Related Experiment Video

Updated: Aug 29, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention

Can M Nguyen1, Robert A Harrington

  • 1Duke Clinical Research Institute, Durham, North Carolina 27705, USA. ca_m_nguyen@hotmail.com

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed

Insights

Glycoprotein (GP) IIb/IIIa receptor antagonists are vital antiplatelet agents for percutaneous coronary intervention (PCI). This review examines their efficacy, tolerability, and optimal use in PCI, addressing current clinical questions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet therapy is crucial in percutaneous coronary intervention (PCI) to prevent acute peri-procedural complications.
  • Glycoprotein (GP) IIb/IIIa receptor antagonists are potent antiplatelet agents evaluated in PCI.
  • Despite established efficacy, questions remain regarding agent variability and optimal use.

Purpose of the Study:

  • To critically review the clinical efficacy and tolerability of GP IIb/IIIa receptor antagonists during PCI.
  • To highlight potential differences among available GP IIb/IIIa agents.
  • To address important issues concerning their clinical practice application.

Main Methods:

  • Systematic review of randomized clinical trials involving GP IIb/IIIa receptor antagonists in PCI.
  • Analysis of efficacy and tolerability data across multiple trials and patient subsets.
  • Comparative assessment of different GP IIb/IIIa agents.

Main Results:

  • Results from over ten randomized clinical trials confirm the efficacy and tolerability of GP IIb/IIIa antagonists in PCI.
  • Variability in efficacy across trials and patient populations exists.
  • Potential clinical differences among the three available GP IIb/IIIa agents warrant further investigation.

Conclusions:

  • GP IIb/IIIa receptor antagonists are effective in reducing adverse outcomes during PCI.
  • Understanding agent-specific profiles and optimizing their use is essential for maximizing patient benefit.
  • Further research is needed to clarify inter-agent differences and refine clinical application strategies.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...